Tesla, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Tesla, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $94.83B | Jan 29, 2026 |
| FY2025 | Dec 31, 2024 | $97.69B | Jan 29, 2026 |
| FY2025 | Dec 31, 2023 | $96.77B | Jan 29, 2026 |
| FY2024 | Dec 31, 2022 | $81.46B | Jan 30, 2025 |
| FY2023 | Dec 31, 2021 | $53.82B | Jan 29, 2024 |
| FY2020 | Dec 31, 2020 | $10.74B | Feb 8, 2021 |
| FY2020 | Sep 30, 2020 | $8.77B | Feb 8, 2021 |
| FY2020 | Jun 30, 2020 | $6.04B | Feb 8, 2021 |
| FY2020 | Mar 31, 2020 | $5.99B | Feb 8, 2021 |
| FY2020 | Dec 31, 2019 | $7.38B | Feb 8, 2021 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $94.83B | Jan 29, 2026 |
| FY2025 | Dec 31, 2024 | $97.69B | Jan 29, 2026 |
| FY2025 | Dec 31, 2023 | $96.77B | Jan 29, 2026 |
| FY2024 | Dec 31, 2022 | $81.46B | Jan 30, 2025 |
| FY2023 | Dec 31, 2021 | $53.82B | Jan 29, 2024 |
| FY2018 | Dec 31, 2018 | $21.46B | Feb 19, 2019 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $17.09B | Jan 29, 2026 |
| FY2025 | Dec 31, 2024 | $17.45B | Jan 29, 2026 |
| FY2025 | Dec 31, 2023 | $17.66B | Jan 29, 2026 |
| FY2024 | Dec 31, 2022 | $20.85B | Jan 30, 2025 |
| FY2023 | Dec 31, 2021 | $13.61B | Jan 29, 2024 |
| FY2020 | Dec 31, 2020 | $2.07B | Feb 8, 2021 |
| FY2020 | Sep 30, 2020 | $2.06B | Feb 8, 2021 |
| FY2020 | Jun 30, 2020 | $1.27B | Feb 8, 2021 |
| FY2020 | Mar 31, 2020 | $1.23B | Feb 8, 2021 |
| FY2020 | Dec 31, 2019 | $1.39B | Feb 8, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.79B | Jan 29, 2026 |
| FY2025 | Dec 31, 2024 | $7.09B | Jan 29, 2026 |
| FY2024 | Sep 30, 2024 | $2.17B | Jan 30, 2025 |
| FY2024 | Jun 30, 2024 | $1.48B | Jan 30, 2025 |
| FY2024 | Mar 31, 2024 | $1.13B | Jan 30, 2025 |
| FY2025 | Dec 31, 2023 | $15.00B | Jan 29, 2026 |
| FY2024 | Dec 31, 2022 | $12.56B | Jan 30, 2025 |
| FY2023 | Dec 31, 2021 | $5.52B | Jan 29, 2024 |
| FY2020 | Dec 31, 2020 | $270.00M | Feb 8, 2021 |
| FY2020 | Sep 30, 2020 | $331.00M | Feb 8, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.36B | Jan 29, 2026 |
| FY2025 | Dec 31, 2024 | $7.08B | Jan 29, 2026 |
| FY2025 | Dec 31, 2023 | $8.89B | Jan 29, 2026 |
| FY2024 | Dec 31, 2022 | $13.66B | Jan 30, 2025 |
| FY2023 | Dec 31, 2021 | $6.52B | Jan 29, 2024 |
| FY2022 | Dec 31, 2020 | $1.99B | Jan 31, 2023 |
| FY2021 | Dec 31, 2019 | ($69.00M) | Feb 7, 2022 |
| FY2020 | Dec 31, 2018 | ($388.00M) | Feb 8, 2021 |
| FY2019 | Dec 31, 2017 | ($1.63B) | Feb 13, 2020 |
| FY2018 | Dec 31, 2016 | ($667.34M) | Feb 19, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.41B | Jan 29, 2026 |
| FY2025 | Dec 31, 2024 | $4.54B | Jan 29, 2026 |
| FY2025 | Dec 31, 2023 | $3.97B | Jan 29, 2026 |
| FY2024 | Dec 31, 2022 | $3.08B | Jan 30, 2025 |
| FY2023 | Dec 31, 2021 | $2.59B | Jan 29, 2024 |
| FY2022 | Dec 31, 2020 | $1.49B | Jan 31, 2023 |
| FY2021 | Dec 31, 2019 | $1.34B | Feb 7, 2022 |
| FY2020 | Dec 31, 2018 | $1.46B | Feb 8, 2021 |
| FY2019 | Dec 31, 2017 | $1.38B | Feb 13, 2020 |
| FY2018 | Dec 31, 2016 | $834.41M | Feb 19, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.83B | Jan 29, 2026 |
| FY2025 | Dec 31, 2024 | $5.15B | Jan 29, 2026 |
| FY2025 | Dec 31, 2023 | $4.80B | Jan 29, 2026 |
| FY2024 | Dec 31, 2022 | $3.95B | Jan 30, 2025 |
| FY2023 | Dec 31, 2021 | $4.52B | Jan 29, 2024 |
| FY2022 | Dec 31, 2020 | $3.15B | Jan 31, 2023 |
| FY2021 | Dec 31, 2019 | $2.65B | Feb 7, 2022 |
| FY2020 | Dec 31, 2018 | $2.84B | Feb 8, 2021 |
| FY2019 | Dec 31, 2017 | $2.48B | Feb 13, 2020 |
| FY2018 | Dec 31, 2016 | $1.43B | Feb 19, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.75B | Jan 29, 2026 |
| FY2025 | Dec 31, 2024 | $14.92B | Jan 29, 2026 |
| FY2025 | Dec 31, 2023 | $13.26B | Jan 29, 2026 |
| FY2024 | Dec 31, 2022 | $14.72B | Jan 30, 2025 |
| FY2023 | Dec 31, 2021 | $11.50B | Jan 29, 2024 |
| FY2022 | Dec 31, 2020 | $5.94B | Jan 31, 2023 |
| FY2021 | Dec 31, 2019 | $2.41B | Feb 7, 2022 |
| FY2020 | Dec 31, 2018 | $2.10B | Feb 8, 2021 |
| FY2019 | Dec 31, 2017 | ($61.00M) | Feb 13, 2020 |
| FY2018 | Dec 31, 2016 | ($123.83M) | Feb 19, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.53B | Jan 29, 2026 |
| FY2025 | Dec 31, 2024 | $11.34B | Jan 29, 2026 |
| FY2025 | Dec 31, 2023 | $8.90B | Jan 29, 2026 |
| FY2024 | Dec 31, 2022 | $7.16B | Jan 30, 2025 |
| FY2023 | Dec 31, 2021 | $6.48B | Jan 29, 2024 |
| FY2022 | Dec 31, 2020 | $3.16B | Jan 31, 2023 |
| FY2021 | Dec 31, 2019 | $1.33B | Feb 7, 2022 |
| FY2020 | Dec 31, 2018 | $2.10B | Feb 8, 2021 |
| FY2019 | Dec 31, 2017 | $3.42B | Feb 13, 2020 |
| FY2018 | Dec 31, 2016 | $1.28B | Feb 19, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $137.81B | Jan 29, 2026 |
| FY2025 | Dec 31, 2024 | $122.07B | Jan 29, 2026 |
| FY2024 | Dec 31, 2023 | $106.62B | Jan 30, 2025 |
| FY2023 | Dec 31, 2022 | $82.34B | Jan 29, 2024 |
| FY2022 | Dec 31, 2021 | $62.13B | Jan 31, 2023 |
| FY2021 | Dec 31, 2020 | $52.15B | Feb 7, 2022 |
| FY2020 | Dec 31, 2019 | $34.31B | Feb 8, 2021 |
| FY2019 | Dec 31, 2018 | $29.74B | Feb 13, 2020 |
| FY2018 | Dec 31, 2017 | $28.66B | Feb 19, 2019 |
| FY2017 | Dec 31, 2016 | $22.66B | Feb 23, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $54.94B | Jan 29, 2026 |
| FY2025 | Dec 31, 2024 | $48.39B | Jan 29, 2026 |
| FY2024 | Dec 31, 2023 | $43.01B | Jan 30, 2025 |
| FY2023 | Dec 31, 2022 | $36.44B | Jan 29, 2024 |
| FY2022 | Dec 31, 2021 | $30.55B | Jan 31, 2023 |
| FY2021 | Dec 31, 2020 | $28.42B | Feb 7, 2022 |
| FY2020 | Dec 31, 2019 | $26.20B | Feb 8, 2021 |
| FY2019 | Dec 31, 2018 | $23.43B | Feb 13, 2020 |
| FY2018 | Dec 31, 2017 | $23.02B | Feb 19, 2019 |
| FY2017 | Dec 31, 2016 | $16.75B | Feb 23, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $82.14B | Jan 29, 2026 |
| FY2025 | Dec 31, 2024 | $72.91B | Jan 29, 2026 |
| FY2024 | Dec 31, 2023 | $62.63B | Jan 30, 2025 |
| FY2023 | Dec 31, 2022 | $44.70B | Jan 29, 2024 |
| FY2022 | Dec 31, 2021 | $30.19B | Jan 31, 2023 |
| FY2021 | Dec 31, 2020 | $22.23B | Feb 7, 2022 |
| FY2020 | Dec 31, 2019 | $6.62B | Feb 8, 2021 |
| FY2019 | Dec 31, 2018 | $4.92B | Feb 13, 2020 |
| FY2018 | Dec 31, 2017 | $4.24B | Feb 19, 2019 |
| FY2017 | Dec 31, 2016 | $4.75B | Feb 23, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $257.00M | Jan 29, 2026 |
| FY2025 | Dec 31, 2024 | $244.00M | Jan 29, 2026 |
| FY2024 | Dec 31, 2023 | $253.00M | Jan 30, 2025 |
| FY2023 | Dec 31, 2022 | $194.00M | Jan 29, 2024 |
| FY2022 | Dec 31, 2021 | $200.00M | Jan 31, 2023 |
| FY2021 | Dec 31, 2020 | $207.00M | Feb 7, 2022 |
| FY2020 | Dec 31, 2019 | $198.00M | Feb 8, 2021 |
| FY2019 | Dec 31, 2018 | $68.00M | Feb 13, 2020 |
| FY2018 | Dec 31, 2017 | $60.24M | Feb 19, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $39.00B | Jan 29, 2026 |
| FY2025 | Dec 31, 2024 | $35.21B | Jan 29, 2026 |
| FY2025 | Jan 1, 2024 | $28.12B | Jan 29, 2026 |
| FY2024 | Dec 31, 2023 | $27.88B | Jan 30, 2025 |
| FY2023 | Dec 31, 2022 | $12.89B | Jan 29, 2024 |
| FY2022 | Dec 31, 2021 | $329.00M | Jan 31, 2023 |
| FY2022 | Jan 1, 2021 | ($5.19B) | Jan 31, 2023 |
| FY2022 | Dec 31, 2020 | ($5.40B) | Jan 31, 2023 |
| FY2020 | Dec 31, 2019 | ($6.08B) | Feb 8, 2021 |
| FY2019 | Dec 31, 2018 | ($5.32B) | Feb 13, 2020 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.51B | Jan 29, 2026 |
| FY2025 | Dec 31, 2024 | $16.14B | Jan 29, 2026 |
| FY2025 | Dec 31, 2023 | $16.40B | Jan 29, 2026 |
| FY2024 | Dec 31, 2022 | $16.25B | Jan 30, 2025 |
| FY2023 | Dec 31, 2021 | $17.58B | Jan 29, 2024 |
| FY2022 | Dec 31, 2020 | $19.38B | Jan 31, 2023 |
| FY2021 | Dec 31, 2019 | $6.27B | Feb 7, 2022 |
| FY2020 | Dec 31, 2018 | $3.69B | Feb 8, 2021 |
| FY2019 | Dec 31, 2017 | $3.37B | Feb 13, 2020 |
| FY2019 | Dec 31, 2016 | $3.39B | Feb 13, 2020 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.58B | Jan 29, 2026 |
| FY2025 | Dec 31, 2024 | $5.54B | Jan 29, 2026 |
| FY2024 | Dec 31, 2023 | $2.68B | Jan 30, 2025 |
| FY2023 | Dec 31, 2022 | $1.03B | Jan 29, 2024 |
| FY2022 | Dec 31, 2021 | $4.25B | Jan 31, 2023 |
| FY2021 | Dec 31, 2020 | $8.46B | Feb 7, 2022 |
| FY2020 | Dec 31, 2019 | $10.40B | Feb 8, 2021 |
| FY2019 | Dec 31, 2018 | $8.41B | Feb 13, 2020 |
| FY2018 | Dec 31, 2017 | $8.83B | Feb 19, 2019 |
| FY2017 | Dec 31, 2016 | $5.89B | Feb 23, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Jan 29, 2026 |
| FY2025 | Dec 31, 2024 | 2 | Jan 29, 2026 |
| FY2024 | Sep 30, 2024 | 0 | Jan 30, 2025 |
| FY2024 | Jun 30, 2024 | 0 | Jan 30, 2025 |
| FY2024 | Mar 31, 2024 | 0 | Jan 30, 2025 |
| FY2025 | Dec 31, 2023 | 4 | Jan 29, 2026 |
| FY2024 | Dec 31, 2022 | 4 | Jan 30, 2025 |
| FY2023 | Dec 31, 2021 | 1 | Jan 29, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Jan 31, 2023 |
| FY2021 | Dec 31, 2019 | 0 | Feb 7, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Jan 29, 2026 |
| FY2025 | Dec 31, 2024 | 2 | Jan 29, 2026 |
| FY2024 | Sep 30, 2024 | 0 | Jan 30, 2025 |
| FY2024 | Jun 30, 2024 | 0 | Jan 30, 2025 |
| FY2024 | Mar 31, 2024 | 0 | Jan 30, 2025 |
| FY2025 | Dec 31, 2023 | 4 | Jan 29, 2026 |
| FY2024 | Dec 31, 2022 | 3 | Jan 30, 2025 |
| FY2023 | Dec 31, 2021 | 1 | Jan 29, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Jan 31, 2023 |
| FY2021 | Dec 31, 2019 | 0 | Feb 7, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3.75B | Jan 29, 2026 |
| FY2025 | Dec 31, 2024 | 3.22B | Jan 29, 2026 |
| FY2024 | Dec 31, 2023 | 3.19B | Jan 30, 2025 |
| FY2023 | Dec 31, 2022 | 3.16B | Jan 29, 2024 |
| FY2022 | Dec 31, 2021 | 3.10B | Jan 31, 2023 |
| FY2021 | Dec 30, 2021 | 1.03B | Feb 7, 2022 |
| FY2021 | Dec 31, 2020 | 960.00M | Feb 7, 2022 |
| FY2020 | Dec 31, 2019 | 905.00M | Feb 8, 2021 |
| FY2019 | Dec 31, 2018 | 173.00M | Feb 13, 2020 |
| FY2018 | Dec 31, 2017 | 168.80M | Feb 19, 2019 |